A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)
Status:
Active, not recruiting
Trial end date:
2021-10-20
Target enrollment:
Participant gender:
Summary
Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in
subjects with iNHL (Follicular Lymphoma, Marginal Zone Lymphoma, or Small Lymphocytic
Lymphoma) that is refractory to rituximab and to either chemotherapy or RIT.